• Lipid Nanoparticles in Cancer Immunotherapy

  2026-10-09

  The 2025 review by Abaza, Mohamed, and Zaky presents lipid nanoparticles as a delivery-centered framework for nucleic acid cancer immunotherapy, linking cargo protection, cellular uptake, biodistribution, and immune modulation. Its main value is synthesis rather than a new formulation or clinical efficacy result, so its conclusions are best used to guide evidence interpretation and study rationale.

• ARCA EGFP mRNA: Evidence, Uses and Limits

  2026-10-08

  A source-grounded overview of ARCA EGFP mRNA as a mammalian-cell reporter, covering fluorescence-based transfection assays, published mRNA-delivery findings, evidence strength, and applicability limits.

• KIR2.1, PASMC Remodeling, and Pulmonary Hypertension

  2026-10-08

  Cao et al. investigated how KIR2.1 relates to pulmonary artery smooth muscle cell proliferation, migration, and pulmonary vascular remodeling. Their complementary animal and cell-based evidence links KIR2.1 inhibition with reduced remodeling-associated phenotypes and suppression of TGF-β1/SMAD2/3 signaling, while also highlighting important limits of pharmacological and model-based interpretation.

• Minocycline HCl: Evidence, Scope and Limits

  2026-10-07

  A source-grounded overview of Minocycline HCl, extracellular-vesicle research, evidence quality, interpretation, applicability and key limitations. The supplied EV study does not test minocycline, so claims about therapeutic synergy or compatibility remain unproven.

• Brain-to-Spinal Control of Opioid Pain Hypersensitivity

  2026-10-07

  A 2024 Neuron study identifies a brain-to-spinal opioid pathway that regulates morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. Its findings shift attention from predominantly peripheral explanations toward coordinated activity across the lateral parabrachial nucleus, hypothalamus, and spinal dorsal horn.

• PreScission Protease: Evidence, Scope and Limits

  2026-10-06

  A source-grounded overview of PreScission Protease and HRV 3C protease, covering cleavage principles, evidence quality, interpretation, applicability, and limitations without providing experimental procedures.

• Puromycin Dihydrochloride: Translation and Glioma

  2026-10-06

  A source-grounded overview of Puromycin dihydrochloride, its conceptual use in selection and translation research, and what the 2024 YANK2–Fyn–p70S6K glioma study does—and does not—show about protein synthesis and tumor biology.

• IDH1-R132H Autopalmitoylation and Cancer

  2026-10-05

  Hu and colleagues report that oncogenic IDH1-R132H is uniquely autopalmitoylated at cysteine 269, linking fatty-acid metabolism to mutant IDH1 activity. The findings suggest that a hydrophobic regulatory pocket may connect lipid availability, 2-HG production, epigenetic remodeling, and a potential therapeutic vulnerability, although validation across broader tumor contexts remains necessary.

• Docetaxel and FOXM1: Context for Resistance Research

  2026-10-05

  A source-grounded overview of Docetaxel, also known as Taxotere, in cancer chemotherapy research, with emphasis on microtubule biology, FOXM1-associated chemoresistance, conceptual applications, evidence strength, and the limits of translating preclinical findings into treatment claims.

• Steroid Lysis of Protoplasts: 1965 Study Explained

  2026-10-04

  Smith and Shay’s 1965 study used bacterial protoplasts to examine how synthetic steroids and stabilizing compounds affected membrane-associated lysis. Its main contribution was methodological: removing the cell wall helped distinguish effects consistent with direct membrane disruption from explanations based mainly on cell-wall permeability or chelation.

• Streptavidin-Cy3 in Biohybrid Microrobot Research

  2026-10-03

  This overview explains how Streptavidin-Cy3 can function as a fluorescent biotin detection reagent in conceptual cancer-biology and biohybrid-microrobot studies. It separates supplier specifications from findings reported by Gong et al. on Euglena-based microrobots, and highlights evidence gaps, interpretation limits, and the absence of direct validation linking the product to that platform.

• Propidium Iodide Workflows for Cell Assays

  2026-10-01

  Build reproducible membrane-integrity, apoptosis, and DNA-content workflows with Propidium iodide, from live-cell screening to fixed-cell flow cytometry. The guide also shows how to interpret PI-positive events cautiously when testing treatment sensitivity in heterogeneous cancer models.

• 2'-O-Methyladenosine: Assay Workflows

  2026-10-01

  Build more reliable nucleoside uptake, RNA modification, and purine metabolism experiments with 2'-O-Methyladenosine. This practical workflow combines controlled dosing, matrix cleanup, isomer-aware UHPLC–MS/MS, and troubleshooting strategies that separate biological signal from ion suppression and handling artifacts.

• Ionomycin Free Acid: Calcium Ionophore for FAK Research

  2026-09-30

  Ionomycin free acid is a calcium ionophore research reagent for controlled intracellular calcium increase. Its documented transport activity supports calcium signaling assays, while the cited TNBC study provides a rationale for using calcium perturbation to interrogate the FAISL–FAK–Calpain 2 axis without treating ionomycin as a validated FAK therapy.

• Euglena Biohybrid Microrobots for Tumor Barriers

  2026-09-30

  Gong and colleagues develop magnetically guided biohybrid microrobots that combine the deformability and autonomous motility of Euglena gracilis with magnetic control and intrinsic algal therapeutic functions. The platform is designed to penetrate dense three-dimensional biological environments, localize around tumor spheroids, and support photodynamic and immune-related treatment without exogenous drug loading.

8588 records 1/573 page Next 12345 下5页 Last page